
Investors should prioritize Infrastructure and Foundation Models over traditional SaaS applications, as AI-driven cloning is rapidly eroding the competitive moats of software-only companies. Keep a close watch on OpenAI and Anthropic, as industry experts predict major model-layer companies may launch IPOs within the next 12 months. In the biotech sector, focus on Eli Lilly (LLY) and companies specializing in Peptide discovery, which are using AI to develop next-generation fat loss and longevity treatments. Consider diversifying into niche Consumer Hardware startups that solve "analog" problems, as physical products currently offer more defensibility against AI commoditization than digital tools. Finally, seek out companies that own Proprietary "Dark" Data—unwritten or private information not found on the public internet—as this is becoming the most valuable asset for training specialized AI.
The discussion centered on the rapid evolution of AI models, specifically the competition between OpenAI, Anthropic, and Google. The speakers noted that the "moat" for software has shifted from engineering effort to network effects and data.
Kevin Rose highlighted a massive investment opportunity in the "Peptide" space, driven by AI-accelerated candidate discovery.
Despite skepticism about consumer software, there is a bullish outlook on niche hardware that facilitates human connection or solves specific "analog" problems.
The podcast touched on broader economic transformations resulting from AI productivity gains.

By Andreessen Horowitz
The a16z Podcast discusses tech and culture trends, news, and the future – especially as ‘software eats the world’. It features industry experts, business leaders, and other interesting thinkers and voices from around the world. This podcast is produced by Andreessen Horowitz (aka “a16z”), a Silicon Valley-based venture capital firm. Multiple episodes are released every week; visit a16z.com for more details and to sign up for our newsletters and other content as well!